

March 6, 2023

Company Name: HEALIOS K.K.
Representative: Hardy TS Kagimoto, Chairman & CEO
(TSE Growth Code: 4593)

TREASURE study results to be presented at STROKE 2023

HEALIOS K.K. (“Healios”) announces that the results of the “TREASURE” study, its clinical trial conducted in Japan for ischemic stroke patients, will be presented in a ‘Symposium 9’ session at STROKE 2023 to be held in Japan from March 16 to 18, 2023.

Date: March 17, 2023, 15:10-16:40 Slot (local time)

Title: TREASURE study ~ Placebo-controlled, double-blind, phase 2/3 trial of allogeneic bone marrow somatic stem cells in acute ischemic stroke ~

Presenter: Toshiya Osanai, M.D., Ph.D., Hokkaido University, Department of Neurosurgery

Venue: Venue 2, PACIFICO Yokohama (1-1-1, Minato Mirai, Nishi-ku, Yokohama 220-0012, JAPAN)

Meeting URL: <https://site2.convention.co.jp/stroke2023/>

About the TREASURE study

The TREASURE study was conducted to investigate the safety and efficacy of HLCM051 (MultiStem®) in patients with ischemic stroke. The study targeted patients with moderate to moderate-severe strokes (baseline NIHSS score 8-20), with administration of a single dose of HLCM051 or placebo intravenously within 18-36 hours from stroke onset. The trial was conducted at 48 sites in Japan and enrolled 206 patients. HLCM051 is an off-the-shelf, somatic stem cell regenerative medicine product that Healios is developing for both ischemic stroke and acute respiratory distress syndrome in Japan.

Contact:
IR & Finance and Accounting Division, HEALIOS K.K.
E-mail: ir@healios.jp